Skip to main content

Pfizer-BioNTech COVID-19 Vaccine Booster Dose for Children Update

Last updated on 5/25/2022

On May 17, 2022, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine as follows:

Authorization of a single booster dose for individuals 5 years through 11 years of age at least 5 months after completion of the primary series with the Pfizer-BioNTech COVID-19 vaccine.

The Texas Health and Human Services Commission allows for pharmacy benefit coverage of the Pfizer-BioNTech COVID-19 vaccine in compliance with the expanded use authorized by the FDA.

Contact with any comments or questions.